Scarica l'app Stockscreener
131.75
0.05%
0.06
Dopo l'orario di chiusura:
131.78
0.03
+0.02%
Precedente Chiudi:
$131.69
Aprire:
$131.75
Volume 24 ore:
1.01M
Relative Volume:
0.37
Capitalizzazione di mercato:
$14.03B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
-151.44
EPS:
-0.87
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+0.11%
1M Prestazione:
+2.73%
6M Prestazione:
+79.74%
1 anno Prestazione:
+88.97%
Intervallo 1D:
$131.71
$131.79
Intervallo di 1 settimana:
$131.51
$131.79
Portata 52W:
$64.09
$131.79
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-01-31 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa
Intra-Cellular Therapies announces proxy statement supplement - Investing.com
Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court - Marketscreener.com
Intra-Cellular Therapies Stock Hits All-Time High of $131.47 By Investing.com - Investing.com UK
Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Scrip M&A Podcast: Looking At M&A Activity As Q1 Nears A Close - Scrip
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 - Investing.com
Jones Financial Companies Lllp Acquires 2,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Charles Schwab Investment Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Long Term Trading Analysis for (ITCI) - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Bank of New York Mellon Corp - Defense World
Lisanti Capital Growth LLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Intra-Cellular Therapies, Inc. to Host Earnings Call - ACCESS Newswire
J&J to stop studies of depression drug due to low effectiveness - Reuters.com
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com - Defense World
Intra-Cellular Therapies progresses in Johnson & Johnson merger By Investing.com - Investing.com Canada
Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Canada Finance
GW&K Investment Management LLC Sells 6,734 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Phocas Financial Corp. Has $241,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Equities Analysts Offer Predictions for ITCI FY2025 Earnings - MarketBeat
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Where are the Opportunities in (ITCI) - Stock Traders Daily
Wealthspire Advisors LLC Acquires New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ING Groep NV Purchases Shares of 12,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho - MarketBeat
HealthInvest Partners AB Sells 13,440 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Ieq Capital LLC - MarketBeat
New York State Common Retirement Fund Has $6.40 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $129 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $129 - Investing.com
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc.ITCI - Business Wire
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - The Bakersfield Californian
Intra-Cellular Therapies Reports Strong 2024 Growth - TipRanks
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Mizuho cuts Intra-Cellular stock rating, lowers price target - Investing.com India
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140 - Marketscreener.com
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week HighWhat's Next? - MarketBeat
Allspring Global Investments Holdings LLC Raises Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):